Montpellier, October 27, 2023 at 6:00 p.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for administering active ingredients in nano micelles orally, Aonys®, announces its half-year results ending June 30 2023, and takes stock of the evolution of its activities.
The unaudited financial statements for the first half of 2023, established in accordance with French accounting standards, were approved by the Management Board at its meeting on October 25 and submitted to the Supervisory Board on the same day.